Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction

Abstract Background Angiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as an innovative therapy for patients of heart failure with reduced ejection fraction (HFrEF). The purpose of this study was to assess the safety and tolerability of Sacubitril/Valsartan in patient with HF...

Full description

Bibliographic Details
Main Authors: Muhammad Nauman Khan, Najia Aslam Soomro, Khalid Naseeb, Usman Hanif Bhatti, Rubina Rauf, Iram Jehan Balouch, Ali Moazzam, Sonia Bashir, Tariq Ashraf, Musa Karim
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cardiovascular Disorders
Subjects:
Sacubitril
Heart failure
Reduced ejection fraction
Safety and tolerability
Online Access:https://doi.org/10.1186/s12872-023-03070-9

Internet

https://doi.org/10.1186/s12872-023-03070-9

Similar Items